Literature DB >> 19230674

Modulation of the immune system by Kaposi's sarcoma-associated herpesvirus.

Cristina Aresté1, David J Blackbourn.   

Abstract

The most recently identified human herpesvirus is Kaposi's sarcoma-associated herpesvirus (KSHV). It causes Kaposi's sarcoma, a tumour occurring most commonly in untreated AIDS patients and the leading cancer of men in certain parts of Africa. KSHV might also contribute to the pathogenesis of primary effusion lymphoma and multicentric Castleman's disease. The genome of KSHV contains 86 genes, almost a quarter of which encode proteins with either demonstrated or potential immunoregulatory activity. They include homologues of cellular proteins and unique KSHV proteins that can deregulate many aspects of the immune response, including T- and B-cell functions, complement activation, the innate antiviral interferon response and natural killer cell activity. The functions of these proteins and the ways in which they perturb the normal immune response are the subjects of the present review.

Entities:  

Mesh:

Year:  2009        PMID: 19230674     DOI: 10.1016/j.tim.2008.12.001

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  45 in total

Review 1.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

2.  Reconstitution of immune responses against Kaposi sarcoma-associated herpesvirus.

Authors:  Roberto Flores; James J Goedert
Journal:  AIDS       Date:  2010-09-10       Impact factor: 4.177

3.  Construction and characterization of an infectious murine gammaherpesivrus-68 bacterial artificial chromosome.

Authors:  Ting-Ting Wu; Hsiang-I Liao; Leming Tong; Ronika Sitapara Leang; Greg Smith; Ren Sun
Journal:  J Biomed Biotechnol       Date:  2010-12-09

Review 4.  Kaposi's sarcoma and its associated herpesvirus.

Authors:  Enrique A Mesri; Ethel Cesarman; Chris Boshoff
Journal:  Nat Rev Cancer       Date:  2010-10       Impact factor: 60.716

5.  Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3.

Authors:  L M Butler; H C Jeffery; R L Wheat; H M Long; P C Rae; G B Nash; D J Blackbourn
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

6.  A Rhesus Rhadinovirus Viral Interferon (IFN) Regulatory Factor Is Virion Associated and Inhibits the Early IFN Antiviral Response.

Authors:  Gabriela Morin; Bridget A Robinson; Kelsey S Rogers; Scott W Wong
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

7.  Kaposi's sarcoma-associated herpesvirus-induced angiogenin plays roles in latency via the phospholipase C gamma pathway: blocking angiogenin inhibits latent gene expression and induces the lytic cycle.

Authors:  Sathish Sadagopan; Mohanan Valiya Veettil; Nitika Paudel; Virginie Bottero; Bala Chandran
Journal:  J Virol       Date:  2011-01-05       Impact factor: 5.103

8.  Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression.

Authors:  Katharina Schmidt; Effi Wies; Frank Neipel
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

9.  Identification of caspase-mediated decay of interferon regulatory factor-3, exploited by a Kaposi sarcoma-associated herpesvirus immunoregulatory protein.

Authors:  Cristina Aresté; Mohamed Mutocheluh; David J Blackbourn
Journal:  J Biol Chem       Date:  2009-06-24       Impact factor: 5.157

10.  The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin.

Authors:  Claire Pardieu; Raphaël Vigan; Sam J Wilson; Alessandra Calvi; Trinity Zang; Paul Bieniasz; Paul Kellam; Greg J Towers; Stuart J D Neil
Journal:  PLoS Pathog       Date:  2010-04-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.